docetaxel Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, taxane derivatives 939 114977-28-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • docetaxel hydrate
  • docetaxel
  • docetaxol
  • docetere
  • taxotel
  • taxotere
  • docetaxel anhydrous
  • RP 56976
  • RP-56976
A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.
  • Molecular weight: 807.89
  • Formula: C43H53NO14
  • CLOGP: 4.08
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 5
  • TPSA: 224.45
  • ALOGS: -4.80
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.15 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 14, 1996 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 3983.60 32.85 1029 11974 9853 2335229
Diarrhoea 3487.57 32.85 1530 11473 82034 2263048
Neutropenia 2929.06 32.85 943 12060 20605 2324477
Nausea 1804.63 32.85 1087 11916 111102 2233980
Pyrexia 1698.43 32.85 818 12185 52890 2292192
Vomiting 1565.32 32.85 850 12153 70752 2274330
Mucosal inflammation 1492.19 32.85 408 12595 4816 2340266
Palmar-plantar erythrodysaesthesia syndrome 1488.07 32.85 389 12614 3812 2341270
Dyspnoea 1424.89 32.85 826 12177 77907 2267175
Fatigue 1317.90 32.85 807 12196 84066 2261016
Disease progression 1094.35 32.85 430 12573 16665 2328417
Dehydration 1089.69 32.85 462 12541 21833 2323249
Malignant neoplasm progression 1070.20 32.85 386 12617 11742 2333340
Neuropathy peripheral 1024.12 32.85 368 12635 11064 2334018
Ejection fraction decreased 950.67 32.85 251 12752 2550 2342532
Anaemia 928.16 32.85 474 12529 34318 2310764
Stomatitis 923.95 32.85 327 12676 9383 2335699
Bone marrow failure 920.31 32.85 286 12717 5400 2339682
Decreased appetite 874.39 32.85 429 12574 28462 2316620
Pleural effusion 854.45 32.85 324 12679 11344 2333738
Leukopenia 837.35 32.85 308 12695 9888 2335194
Asthenia 829.51 32.85 487 12516 46439 2298643
Alopecia 822.34 32.85 378 12625 21623 2323459
Abdominal pain 742.22 32.85 407 12596 33967 2311115
Erythema 726.14 32.85 362 12641 24797 2320285
Neutropenic sepsis 644.38 32.85 161 12842 1281 2343801
Metastases to liver 626.57 32.85 183 12820 2758 2342324
Metastases to bone 622.42 32.85 172 12831 2097 2342985
Hypokalaemia 621.21 32.85 251 12752 10403 2334679
Interstitial lung disease 607.86 32.85 227 12776 7585 2337497
Colitis 581.34 32.85 198 12805 5028 2340054
Myalgia 569.21 32.85 300 12703 23033 2322049
White blood cell count decreased 566.46 32.85 276 12727 17932 2327150
Neutrophil count decreased 559.38 32.85 204 12799 6363 2338719
Sepsis 544.54 32.85 270 12733 18218 2326864
Breast cancer 540.69 32.85 220 12783 9275 2335807
General physical health deterioration 527.55 32.85 243 12760 13896 2331186
Thrombocytopenia 521.13 32.85 265 12738 18866 2326216
Pneumonia 518.97 32.85 370 12633 48926 2296156
Acute myeloid leukaemia 517.64 32.85 155 12848 2555 2342527
Rash 495.31 32.85 388 12615 59170 2285912
Back pain 488.96 32.85 302 12701 31357 2313725
Constipation 484.88 32.85 263 12740 21366 2323716
Flushing 480.53 32.85 216 12787 11655 2333427
Cough 458.99 32.85 295 12708 32822 2312260
Polyneuropathy 434.77 32.85 123 12880 1640 2343442
Peripheral sensory neuropathy 430.24 32.85 109 12894 921 2344161
Metastases to lung 396.42 32.85 114 12889 1617 2343465
Oedema peripheral 385.20 32.85 234 12769 23529 2321553
Hypotension 383.98 32.85 262 12741 32174 2312908
Skin toxicity 381.92 32.85 94 12909 696 2344386
Arthralgia 379.69 32.85 320 12683 53965 2291117
Dysgeusia 371.28 32.85 163 12840 8296 2336786
Epistaxis 364.21 32.85 168 12835 9611 2335471
Skin exfoliation 359.89 32.85 143 12860 5647 2339435
Metastases to central nervous system 359.41 32.85 111 12892 2037 2343045
Agranulocytosis 352.36 32.85 123 12880 3359 2341723
Cellulitis 348.68 32.85 160 12843 9041 2336041
Neoplasm progression 331.48 32.85 127 12876 4541 2340541
Pain 330.04 32.85 313 12690 61544 2283538
Infusion related reaction 329.90 32.85 157 12846 9639 2335443
Cardiac failure 324.44 32.85 166 12837 11928 2333154
Bone pain 320.81 32.85 150 12853 8846 2336236
Septic shock 316.22 32.85 138 12865 6916 2338166
Urinary tract infection 314.80 32.85 225 12778 29717 2315365
Cardiotoxicity 311.94 32.85 88 12915 1159 2343923
Chest discomfort 306.03 32.85 170 12833 14425 2330657
Pneumonitis 305.20 32.85 115 12888 3924 2341158
Lacrimation increased 301.88 32.85 104 12899 2726 2342356
Breast cancer metastatic 297.24 32.85 96 12907 2048 2343034
Acute kidney injury 297.13 32.85 212 12791 27910 2317172
Left ventricular dysfunction 285.38 32.85 82 12921 1158 2343924
Ascites 285.01 32.85 120 12883 5500 2339582
Onycholysis 282.98 32.85 61 12942 226 2344856
Infection 270.16 32.85 169 12834 17860 2327222
Haemoglobin decreased 269.11 32.85 169 12834 17982 2327100
Weight decreased 268.20 32.85 200 12803 28171 2316911
Respiratory failure 265.72 32.85 151 12852 13377 2331705
Lymphoedema 264.76 32.85 76 12927 1069 2344013
Pulmonary embolism 259.66 32.85 165 12838 17918 2327164
Hypersensitivity 251.73 32.85 179 12824 23414 2321668
Malaise 245.54 32.85 254 12749 55331 2289751
Disease recurrence 241.76 32.85 93 12910 3358 2341724
Haematotoxicity 241.22 32.85 71 12932 1096 2343986
Dizziness 241.20 32.85 258 12745 58407 2286675
Chills 241.09 32.85 149 12854 15403 2329679
Paraesthesia 231.96 32.85 166 12837 21922 2323160
Hypoaesthesia 231.02 32.85 160 12843 20055 2325027
Neutropenic colitis 229.97 32.85 52 12951 252 2344830
Nail disorder 229.93 32.85 68 12935 1068 2344014
Alanine aminotransferase increased 226.57 32.85 138 12865 13894 2331188
Pancytopenia 225.31 32.85 128 12875 11324 2333758
Hyponatraemia 222.74 32.85 134 12869 13191 2331891
Metastases to lymph nodes 221.90 32.85 64 12939 916 2344166
Neutropenic infection 219.83 32.85 46 12957 142 2344940
Intestinal perforation 219.23 32.85 73 12930 1718 2343364
Pain in extremity 218.30 32.85 211 12792 42329 2302753
Hypocalcaemia 217.38 32.85 89 12914 3794 2341288
Platelet count decreased 216.33 32.85 140 12863 15673 2329409
Aspartate aminotransferase increased 208.65 32.85 126 12877 12486 2332596
Second primary malignancy 207.02 32.85 61 12942 945 2344137
Lung infiltration 206.23 32.85 74 12929 2190 2342892
Chest pain 204.61 32.85 170 12833 27967 2317115
Febrile bone marrow aplasia 203.13 32.85 58 12945 799 2344283
Gastrointestinal toxicity 200.83 32.85 53 12950 533 2344549
Tachycardia 199.56 32.85 135 12868 16274 2328808
Pericardial effusion 197.87 32.85 84 12919 3925 2341157
Neurotoxicity 195.45 32.85 70 12933 2060 2343022
Death 194.11 32.85 272 12731 81196 2263886
Breast cancer recurrent 187.25 32.85 53 12950 706 2344376
Hypoxia 185.99 32.85 92 12911 6135 2338947
Cardiomyopathy 180.14 32.85 71 12932 2736 2342346
Oedema 179.30 32.85 106 12897 10097 2334985
Gastrointestinal necrosis 168.97 32.85 47 12956 585 2344497
Metastasis 168.22 32.85 51 12952 875 2344207
Oxygen saturation decreased 163.32 32.85 90 12913 7496 2337586
Dysuria 163.28 32.85 73 12930 3868 2341214
Hot flush 162.15 32.85 88 12915 7111 2337971
Lower respiratory tract infection 158.60 32.85 79 12924 5345 2339737
Hepatic failure 157.95 32.85 80 12923 5609 2339473
Large intestine perforation 152.69 32.85 51 12952 1211 2343871
Pruritus 152.62 32.85 176 12827 43164 2301918
Headache 152.49 32.85 241 12762 79938 2265144
Gastritis 149.74 32.85 72 12931 4509 2340573
Hypomagnesaemia 147.69 32.85 60 12943 2504 2342578
Haematocrit decreased 147.64 32.85 70 12933 4248 2340834
Enterocolitis 147.19 32.85 45 12958 795 2344287
Dysphagia 145.33 32.85 101 12902 12704 2332378
Toxicity to various agents 144.85 32.85 150 12853 32604 2312478
Intestinal ischaemia 139.62 32.85 46 12957 1045 2344037
Blood lactate dehydrogenase increased 139.44 32.85 63 12940 3421 2341661
Hyperglycaemia 139.43 32.85 70 12933 4815 2340267
Capillary leak syndrome 138.14 32.85 36 12967 343 2344739
Dyspepsia 136.61 32.85 88 12915 9756 2335326
Pneumothorax 136.25 32.85 55 12948 2257 2342825
Blood creatinine increased 136.01 32.85 90 12913 10443 2334639
Abdominal pain upper 135.11 32.85 121 12882 21979 2323103
C-reactive protein increased 134.05 32.85 74 12929 6181 2338901
Blood alkaline phosphatase increased 133.63 32.85 75 12928 6470 2338612
Multiple organ dysfunction syndrome 130.59 32.85 78 12925 7563 2337519
Dermatitis 127.90 32.85 53 12950 2327 2342755
Myelodysplastic syndrome 127.49 32.85 54 12949 2506 2342576
Acute respiratory distress syndrome 126.91 32.85 58 12945 3234 2341848
Erysipelas 126.38 32.85 42 12961 981 2344101
Onychomadesis 123.58 32.85 35 12968 467 2344615
Lethargy 123.50 32.85 79 12924 8651 2336431
Atrial fibrillation 123.07 32.85 94 12909 13674 2331408
Muscular weakness 122.93 32.85 97 12906 14800 2330282
Nail toxicity 122.41 32.85 24 12979 47 2345035
Hypophagia 122.09 32.85 60 12943 3940 2341142
Dyspnoea exertional 120.73 32.85 67 12936 5653 2339429
Syncope 120.53 32.85 101 12902 16774 2328308
Metastases to skin 119.80 32.85 29 12974 198 2344884
Feeling hot 119.12 32.85 71 12932 6857 2338225
Blister 118.00 32.85 70 12933 6701 2338381
Gamma-glutamyltransferase increased 116.98 32.85 65 12938 5497 2339585
Pseudocirrhosis 116.94 32.85 25 12978 88 2344994
Skin reaction 115.93 32.85 47 12956 1950 2343132
White blood cell count increased 115.13 32.85 70 12933 7008 2338074
Hepatic function abnormal 114.12 32.85 66 12937 6026 2339056
Oral candidiasis 113.22 32.85 46 12957 1919 2343163
Blood sodium decreased 111.33 32.85 52 12951 3048 2342034
Enterocolitis infectious 109.86 32.85 27 12976 198 2344884
Cardiac arrest 105.86 32.85 89 12914 14841 2330241
Oesophagitis 105.53 32.85 44 12959 1962 2343120
Cognitive disorder 105.34 32.85 60 12943 5321 2339761
Morphoea 104.85 32.85 22 12981 69 2345013
Off label use 103.89 32.85 194 12809 73404 2271678
Pulmonary mass 103.86 32.85 43 12960 1883 2343199
Nasopharyngitis 102.85 32.85 104 12899 21952 2323130
Recall phenomenon 101.05 32.85 25 12978 189 2344893
Colitis ischaemic 100.10 32.85 40 12963 1597 2343485
Hypertension 99.36 32.85 113 12890 27248 2317834
Peripheral swelling 99.00 32.85 92 12911 17505 2327577
Invasive ductal breast carcinoma 98.57 32.85 34 12969 892 2344190
Disseminated intravascular coagulation 98.52 32.85 49 12954 3301 2341781
Lymphocyte count decreased 98.34 32.85 49 12954 3314 2341768
Oral pain 97.87 32.85 49 12954 3348 2341734
Deep vein thrombosis 97.73 32.85 80 12923 12852 2332230
Clostridium difficile colitis 97.40 32.85 42 12961 2037 2343045
Hyperhidrosis 97.30 32.85 86 12917 15336 2329746
Sensory disturbance 97.16 32.85 45 12958 2587 2342495
Dry skin 96.07 32.85 61 12942 6591 2338491
Gait disturbance 95.55 32.85 101 12902 22444 2322638
Respiratory distress 94.56 32.85 55 12948 5074 2340008
Embolism 94.11 32.85 36 12967 1277 2343805
Device related infection 93.86 32.85 47 12956 3212 2341870
Myositis 93.53 32.85 36 12967 1299 2343783
Heart rate increased 90.92 32.85 72 12931 11033 2334049
Gastroenteritis 90.70 32.85 45 12958 3015 2342067
Blood potassium decreased 90.23 32.85 54 12949 5251 2339831
Leukocytosis 89.74 32.85 47 12956 3529 2341553
Congestive cardiomyopathy 89.65 32.85 32 12971 931 2344151
Nail dystrophy 89.07 32.85 19 12984 66 2345016
Peritonitis 88.80 32.85 42 12961 2532 2342550
Renal failure 88.63 32.85 86 12917 17263 2327819
Electrolyte imbalance 88.42 32.85 39 12964 1998 2343084
Productive cough 87.49 32.85 53 12950 5268 2339814
Inflammation 87.30 32.85 56 12947 6157 2338925
Blood bilirubin increased 87.27 32.85 53 12950 5292 2339790
Oropharyngeal pain 86.50 32.85 71 12932 11447 2333635
Swelling 85.31 32.85 82 12921 16268 2328814
Anxiety 84.87 32.85 108 12895 29251 2315831
Rhinorrhoea 84.68 32.85 59 12944 7441 2337641
Clostridium difficile infection 84.18 32.85 42 12961 2848 2342234
Pulmonary oedema 83.31 32.85 58 12945 7305 2337777
Palpitations 82.98 32.85 81 12922 16375 2328707
Paronychia 82.94 32.85 29 12974 793 2344289
Metastatic neoplasm 82.71 32.85 28 12975 693 2344389
Tumour lysis syndrome 82.56 32.85 31 12972 1044 2344038
Abdominal distension 82.02 32.85 66 12937 10345 2334737
Pharyngitis 81.83 32.85 38 12965 2197 2342885
Cardiac failure congestive 80.72 32.85 79 12924 16022 2329060
Circulatory collapse 79.65 32.85 44 12959 3676 2341406
Drug intolerance 79.63 32.85 73 12930 13644 2331438
Red cell distribution width increased 79.47 32.85 26 12977 577 2344505
Acute leukaemia 78.19 32.85 22 12981 286 2344796
Odynophagia 78.19 32.85 29 12974 943 2344139
Organising pneumonia 77.53 32.85 28 12975 843 2344239
Generalised oedema 76.18 32.85 37 12966 2366 2342716
Sinus tachycardia 75.82 32.85 41 12962 3284 2341798
Mastectomy 74.22 32.85 21 12982 279 2344803
Radiation skin injury 73.96 32.85 19 12984 170 2344912
Metastases to peritoneum 73.75 32.85 23 12980 435 2344647
Portal hypertension 73.59 32.85 24 12979 527 2344555
Lymphangiosis carcinomatosa 73.57 32.85 20 12983 227 2344855
Musculoskeletal pain 73.55 32.85 63 12940 10767 2334315
Metastases to meninges 72.84 32.85 22 12981 372 2344710
Phlebitis 72.51 32.85 28 12975 1019 2344063
Skin disorder 72.44 32.85 41 12962 3590 2341492
Cardiac tamponade 71.99 32.85 26 12977 783 2344299
Tongue coated 70.93 32.85 19 12984 203 2344879
Diverticulitis 69.79 32.85 42 12961 4123 2340959
Cardiac disorder 68.90 32.85 53 12950 7780 2337302
Lung disorder 68.10 32.85 48 12955 6164 2338918
Hypoalbuminaemia 68.06 32.85 29 12974 1365 2343717
Atelectasis 67.59 32.85 32 12971 1933 2343149
Drug resistance 67.30 32.85 35 12968 2589 2342493
Disturbance in attention 67.17 32.85 46 12957 5639 2339443
Candida infection 67.11 32.85 36 12967 2837 2342245
Insomnia 66.95 32.85 90 12913 25697 2319385
Nail discolouration 66.54 32.85 22 12981 505 2344577
Red blood cell count decreased 66.31 32.85 41 12962 4225 2340857
Periarticular thenar erythema with onycholysis 66.18 32.85 11 12992 2 2345080
Vascular device infection 65.95 32.85 20 12983 343 2344739
Haematemesis 65.41 32.85 40 12963 4042 2341040
Blood pressure decreased 65.32 32.85 55 12948 9181 2335901
Dysaesthesia 65.19 32.85 23 12980 646 2344436
Anaphylactic reaction 64.97 32.85 56 12947 9649 2335433
Clostridial infection 64.72 32.85 24 12979 780 2344302
Skin fissures 64.32 32.85 27 12976 1224 2343858
Abscess 64.00 32.85 33 12970 2398 2342684
Malnutrition 63.98 32.85 30 12973 1773 2343309
Skin infection 63.70 32.85 28 12975 1422 2343660
Rectal haemorrhage 63.61 32.85 45 12958 5811 2339271
Monocyte count decreased 63.55 32.85 18 12985 240 2344842
Ventricular hypokinesia 62.97 32.85 22 12981 600 2344482
Retinal detachment 62.90 32.85 26 12977 1133 2343949
Seroma 62.48 32.85 18 12985 256 2344826
Burning sensation 62.44 32.85 50 12953 7778 2337304
Breast pain 61.94 32.85 27 12976 1344 2343738
Therapeutic response decreased 61.79 32.85 48 12955 7147 2337935
Blood calcium decreased 61.78 32.85 31 12972 2127 2342955
Drug ineffective 61.47 32.85 193 12810 101431 2243651
Body temperature increased 61.09 32.85 35 12968 3136 2341946
Gastrointestinal haemorrhage 60.42 32.85 60 12943 12375 2332707
Cachexia 60.33 32.85 23 12980 808 2344274
Sudden death 60.05 32.85 29 12974 1831 2343251
Gastrooesophageal reflux disease 59.91 32.85 52 12951 9043 2336039
Blood pressure increased 59.66 32.85 69 12934 16917 2328165
Mouth ulceration 59.29 32.85 37 12966 3875 2341207
Shock 58.50 32.85 37 12966 3967 2341115
Respiratory tract infection 58.29 32.85 37 12966 3992 2341090
Osteosclerosis 58.29 32.85 18 12985 329 2344753
Hepatotoxicity 58.06 32.85 35 12968 3446 2341636
Dry mouth 58.05 32.85 49 12954 8204 2336878
Aortitis 57.90 32.85 14 12989 95 2344987
Dermatitis exfoliative 57.89 32.85 25 12978 1216 2343866
Thrombosis 57.66 32.85 51 12952 9093 2335989
Osteolysis 57.64 32.85 19 12984 432 2344650
Skin discolouration 57.37 32.85 41 12962 5379 2339703
Cystitis noninfective 57.35 32.85 15 12988 145 2344937
Dermatitis acneiform 57.33 32.85 22 12981 787 2344295
Sleep disorder 57.27 32.85 44 12959 6445 2338637
Discomfort 56.86 32.85 40 12963 5119 2339963
Pulmonary fibrosis 55.89 32.85 31 12972 2609 2342473
Hepatic lesion 55.70 32.85 20 12983 592 2344490
Subclavian vein thrombosis 55.38 32.85 16 12987 230 2344852
Skin hyperpigmentation 54.82 32.85 22 12981 888 2344194
Blood creatinine decreased 54.56 32.85 19 12984 513 2344569
Influenza like illness 54.38 32.85 56 12947 12058 2333024
Dermatomyositis 54.20 32.85 18 12985 419 2344663
Vulvovaginal dryness 54.20 32.85 18 12985 419 2344663
Mitral valve incompetence 54.14 32.85 30 12973 2520 2342562
Bone marrow infiltration 53.96 32.85 12 12991 53 2345029
Haematuria 53.54 32.85 36 12967 4282 2340800
Rhinitis 53.51 32.85 23 12980 1106 2343976
Respiratory rate increased 53.03 32.85 25 12978 1495 2343587
Wound dehiscence 52.99 32.85 20 12983 683 2344399
Photosensitivity reaction 52.76 32.85 29 12974 2398 2342684
Loss of consciousness 52.56 32.85 68 12935 18699 2326383
Muscle spasms 52.54 32.85 73 12930 21493 2323589
Hyperpyrexia 52.30 32.85 19 12984 582 2344500
Supraventricular tachycardia 52.10 32.85 27 12976 1982 2343100
Blood albumin decreased 52.01 32.85 26 12977 1769 2343313
Blood urea increased 51.89 32.85 33 12970 3572 2341510
Urinary retention 51.37 32.85 33 12970 3634 2341448
Extravasation 51.27 32.85 20 12983 748 2344334
Liver disorder 51.22 32.85 41 12962 6373 2338709
Desmoplastic small round cell tumour 51.05 32.85 9 12994 6 2345076
Systemic scleroderma 50.86 32.85 14 12989 167 2344915
Pollakiuria 50.65 32.85 33 12970 3723 2341359
Recurrent cancer 50.46 32.85 16 12987 320 2344762
Peripheral motor neuropathy 50.32 32.85 15 12988 242 2344840
Throat tightness 50.30 32.85 35 12968 4401 2340681
Dermatitis bullous 50.22 32.85 24 12979 1480 2343602
Haemoptysis 50.05 32.85 32 12971 3495 2341587
Thermal burn 50.05 32.85 20 12983 798 2344284
Small intestinal obstruction 49.57 32.85 27 12976 2193 2342889
Rash erythematous 49.43 32.85 39 12964 5937 2339145
Dysphonia 49.38 32.85 40 12963 6324 2338758
Pneumocystis jirovecii pneumonia 48.97 32.85 27 12976 2246 2342836
Atypical pneumonia 48.92 32.85 18 12985 572 2344510
Gastrointestinal disorder 48.92 32.85 46 12957 8871 2336211
Hypovolaemia 48.90 32.85 22 12981 1181 2343901
Vertigo 48.80 32.85 47 12956 9337 2335745
Nervous system disorder 48.56 32.85 30 12973 3086 2341996
Depression 48.38 32.85 81 12922 28051 2317031
Mastitis 48.03 32.85 17 12986 482 2344600
Obstructive shock 48.03 32.85 9 12994 12 2345070
Paraparesis 47.92 32.85 16 12987 379 2344703
Onychalgia 47.86 32.85 13 12990 147 2344935
Enteritis 47.80 32.85 21 12982 1065 2344017
Performance status decreased 47.74 32.85 18 12985 613 2344469
Carotidynia 47.68 32.85 8 12995 2 2345080
Conjunctivitis 47.67 32.85 27 12976 2366 2342716
Wound infection 47.38 32.85 22 12981 1271 2343811
Granulocytopenia 47.06 32.85 22 12981 1291 2343791
Pericarditis 46.68 32.85 23 12980 1517 2343565
Toxic skin eruption 46.38 32.85 26 12977 2234 2342848
Weight increased 46.23 32.85 70 12933 22267 2322815
Skin lesion 46.20 32.85 32 12971 3993 2341089
Skin ulcer 45.96 32.85 32 12971 4027 2341055
Hypersensitivity pneumonitis 45.91 32.85 16 12987 433 2344649
Fluid retention 45.82 32.85 40 12963 7006 2338076
Tinnitus 45.71 32.85 35 12968 5100 2339982
Mucosal disorder 45.53 32.85 16 12987 444 2344638
Seizure 45.52 32.85 73 12930 24393 2320689
Biopsy lung abnormal 45.13 32.85 9 12994 20 2345062
Abdominal pain lower 45.10 32.85 28 12975 2905 2342177
Cystitis 44.91 32.85 36 12967 5606 2339476
Arrhythmia 44.90 32.85 37 12966 5991 2339091
Speech disorder 44.68 32.85 38 12965 6426 2338656
Lymphadenopathy 44.60 32.85 36 12967 5662 2339420
Metastases to spine 44.47 32.85 15 12988 367 2344715
Nephritis bacterial 44.44 32.85 8 12995 7 2345075
Lymphopenia 44.38 32.85 26 12977 2428 2342654
Dacryostenosis acquired 44.31 32.85 12 12991 134 2344948
Vascular fragility 44.25 32.85 9 12994 23 2345059
Blood magnesium decreased 44 32.85 21 12982 1291 2343791
Triple negative breast cancer 43.97 32.85 9 12994 24 2345058
Febrile infection 43.94 32.85 13 12990 204 2344878
Body temperature decreased 43.83 32.85 21 12982 1302 2343780
Ageusia 43.78 32.85 24 12979 1974 2343108
Rash pustular 43.36 32.85 22 12981 1545 2343537
Bronchial polyp 43.28 32.85 7 12996 0 2345082
Cardiovascular disorder 42.72 32.85 25 12978 2330 2342752
Pseudomembranous colitis 42.63 32.85 16 12987 538 2344544
Rash maculo-papular 42.34 32.85 31 12972 4221 2340861
Bronchitis 42.05 32.85 52 12951 13662 2331420
Multifocal micronodular pneumocyte hyperplasia 41.52 32.85 7 12996 2 2345080
Cerebral infarction 41.16 32.85 31 12972 4406 2340676
Neuralgia 41.03 32.85 26 12977 2796 2342286
Vein disorder 40.98 32.85 16 12987 600 2344482
Proteinuria 40.79 32.85 26 12977 2824 2342258
HER-2 positive breast cancer 40.72 32.85 10 12993 73 2345009
Haemorrhoids 40.66 32.85 24 12979 2273 2342809
Cyanosis 40.55 32.85 27 12976 3158 2341924
Thrombotic microangiopathy 40.48 32.85 20 12983 1327 2343755
Pancreatitis acute 40.44 32.85 29 12974 3824 2341258
Hypovolaemic shock 39.95 32.85 17 12986 797 2344285
Mucosal infection 39.89 32.85 9 12994 43 2345039
Face oedema 39.80 32.85 29 12974 3919 2341163
Malignant pleural effusion 39.48 32.85 14 12989 399 2344683
Onychoclasis 39.36 32.85 17 12986 827 2344255
Vessel puncture site bruise 39.18 32.85 8 12995 21 2345061
Laryngitis 39.17 32.85 20 12983 1423 2343659
Haemorrhage 39.01 32.85 45 12958 10994 2334088
Vascular pain 38.95 32.85 11 12992 145 2344937
Hyperthermia 38.85 32.85 20 12983 1448 2343634
Liver function test increased 38.79 32.85 26 12977 3075 2342007
Visual impairment 38.36 32.85 46 12957 11709 2333373
Staphylococcal infection 38.23 32.85 32 12971 5294 2339788
Gastrointestinal perforation 38.11 32.85 16 12987 725 2344357
Abdominal discomfort 37.97 32.85 56 12947 17400 2327682
Merycism 37.91 32.85 8 12995 26 2345056
Blood pressure systolic decreased 37.83 32.85 16 12987 739 2344343
Skin necrosis 37.61 32.85 18 12985 1113 2343969
Acute promyelocytic leukaemia 37.57 32.85 12 12991 246 2344836
Bone disorder 37.38 32.85 26 12977 3266 2341816
Musculoskeletal chest pain 37.34 32.85 23 12980 2353 2342729
Pelvic abscess 37.12 32.85 12 12991 256 2344826
Menstrual disorder 37.11 32.85 17 12986 952 2344130
Product use in unapproved indication 36.83 32.85 44 12959 11156 2333926
Tumour embolism 36.81 32.85 8 12995 31 2345051
Blood creatine increased 36.74 32.85 15 12988 633 2344449
Pleuritic pain 36.67 32.85 15 12988 636 2344446
Ileus 36.63 32.85 22 12981 2150 2342932
Lymphangitis 36.47 32.85 11 12992 185 2344897
Posterior reversible encephalopathy syndrome 36.43 32.85 23 12980 2457 2342625
Protein total decreased 36.37 32.85 16 12987 814 2344268
Ataxia 36.33 32.85 23 12980 2469 2342613
Large intestine infection 35.98 32.85 11 12992 194 2344888
Intracardiac thrombus 35.95 32.85 14 12989 521 2344561
Infusion site extravasation 35.34 32.85 15 12988 699 2344383
White blood cell count abnormal 35.32 32.85 15 12988 700 2344382
Alveolitis 34.69 32.85 13 12990 435 2344647
Choroidal effusion 34.60 32.85 10 12993 144 2344938
Folliculitis 34.38 32.85 14 12989 587 2344495
Fibrous histiocytoma 34.22 32.85 9 12994 89 2344993
Urticaria 34.14 32.85 64 12939 24197 2320885
Appendiceal abscess 33.93 32.85 8 12995 48 2345034
Transaminases increased 33.84 32.85 28 12975 4559 2340523
Renal impairment 33.76 32.85 40 12963 10052 2335030
Infusion site vesicles 33.65 32.85 8 12995 50 2345032
Pleural disorder 33.61 32.85 9 12994 96 2344986
Glossodynia 33.58 32.85 20 12983 1925 2343157
Computerised tomogram thorax abnormal 33.56 32.85 10 12993 161 2344921
Vena cava thrombosis 33.45 32.85 12 12991 354 2344728
Jaundice 33.28 32.85 30 12973 5478 2339604
Neutrophil count increased 33.02 32.85 20 12983 1985 2343097
Blindness 32.94 32.85 25 12978 3593 2341489

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 2083.59 45.54 613 6800 10487 1728881
Diarrhoea 1580.05 45.54 760 6653 53092 1686276
Neutropenia 1362.13 45.54 503 6910 17757 1721611
Dehydration 1092.83 45.54 425 6988 17233 1722135
Interstitial lung disease 892.15 45.54 313 7100 9383 1729985
Pneumonia 828.76 45.54 472 6941 45710 1693658
Pyrexia 815.85 45.54 468 6945 45932 1693436
Dyspnoea 791.82 45.54 478 6935 51581 1687787
Nausea 765.24 45.54 465 6948 50731 1688637
Anaemia 669.96 45.54 353 7060 29104 1710264
Vomiting 622.53 45.54 368 7045 37947 1701421
Malignant neoplasm progression 617.47 45.54 266 7147 13892 1725476
Mucosal inflammation 595.99 45.54 188 7225 3981 1735387
Decreased appetite 576.06 45.54 298 7115 23573 1715795
Stomatitis 551.99 45.54 189 7224 5215 1734153
Disease progression 551.41 45.54 261 7152 17002 1722366
Fatigue 546.37 45.54 376 7037 50405 1688963
Leukopenia 521.51 45.54 204 7209 8276 1731092
Neutrophil count decreased 515.02 45.54 185 7228 5896 1733472
White blood cell count decreased 507.91 45.54 227 7186 12922 1726446
Respiratory failure 477.25 45.54 224 7189 14281 1725087
Neutropenic sepsis 424.91 45.54 115 7298 1377 1737991
Septic shock 418.37 45.54 172 7241 7937 1731431
Hypotension 401.10 45.54 254 7159 29400 1709968
Pneumonitis 384.16 45.54 133 7280 3782 1735586
Hyponatraemia 381.33 45.54 166 7247 8834 1730534
Sepsis 362.65 45.54 205 7208 19233 1720135
Asthenia 360.18 45.54 252 7161 34418 1704950
Pleural effusion 360.13 45.54 170 7243 10940 1728428
General physical health deterioration 356.82 45.54 178 7235 12940 1726428
Hypokalaemia 344.97 45.54 140 7273 6234 1733134
Bone marrow failure 311.78 45.54 123 7290 5077 1734291
Acute kidney injury 290.11 45.54 222 7191 34722 1704646
Abdominal pain 279.78 45.54 180 7233 21310 1718058
Thrombocytopenia 244.91 45.54 165 7248 21084 1718284
Pulmonary embolism 241.12 45.54 137 7276 12922 1726446
Dysphagia 238.50 45.54 125 7288 10043 1729325
Erythema 238.45 45.54 140 7273 14048 1725320
Alopecia 236.21 45.54 92 7321 3661 1735707
Hypoxia 229.71 45.54 103 7310 5860 1733508
Acute respiratory distress syndrome 223.30 45.54 87 7326 3464 1735904
Hypophagia 221.04 45.54 86 7327 3411 1735957
Osteonecrosis of jaw 220.61 45.54 91 7322 4212 1735156
Disseminated intravascular coagulation 214.78 45.54 85 7328 3529 1735839
Oedema peripheral 201.46 45.54 130 7283 15420 1723948
Hypocalcaemia 200.81 45.54 78 7335 3078 1736290
Haemoglobin decreased 199.68 45.54 134 7279 16980 1722388
Renal failure 185.24 45.54 136 7277 19881 1719487
Pain 181.46 45.54 151 7262 26506 1712862
Atrial fibrillation 180.26 45.54 120 7293 14991 1724377
Neuropathy peripheral 175.84 45.54 99 7314 9154 1730214
Palmar-plantar erythrodysaesthesia syndrome 175.77 45.54 73 7340 3434 1735934
Pneumothorax 168.88 45.54 66 7347 2646 1736722
Constipation 164.29 45.54 113 7300 14887 1724481
Malaise 161.96 45.54 148 7265 29417 1709951
Multiple organ dysfunction syndrome 157.18 45.54 92 7321 9150 1730218
Prostatic specific antigen increased 155.14 45.54 61 7352 2485 1736883
Platelet count decreased 154.44 45.54 113 7300 16410 1722958
Pneumonia aspiration 153.32 45.54 75 7338 5191 1734177
Onycholysis 147.58 45.54 30 7383 83 1739285
Neoplasm progression 143.72 45.54 62 7351 3205 1736163
Metastases to bone 143.47 45.54 52 7361 1686 1737682
Blood creatinine increased 143.18 45.54 101 7312 13845 1725523
Cough 139.38 45.54 113 7300 19084 1720284
Weight decreased 132.54 45.54 118 7295 22635 1716733
Haemoptysis 131.70 45.54 66 7347 4810 1734558
Haematotoxicity 131.58 45.54 42 7371 916 1738452
Condition aggravated 127.79 45.54 112 7301 21038 1718330
Peripheral sensory neuropathy 127.59 45.54 40 7373 821 1738547
Death 127.08 45.54 225 7188 87218 1652150
Chest pain 125.44 45.54 108 7305 19806 1719562
Pancytopenia 125.31 45.54 86 7327 11271 1728097
Skin toxicity 123.96 45.54 36 7377 563 1738805
Metastases to lung 119.53 45.54 44 7369 1491 1737877
Deep vein thrombosis 118.69 45.54 79 7334 9841 1729527
Productive cough 116.17 45.54 55 7358 3536 1735832
Pulmonary toxicity 116.12 45.54 37 7376 802 1738566
Chills 116.11 45.54 83 7330 11604 1727764
Colitis 114.11 45.54 57 7356 4123 1735245
Off label use 113.99 45.54 139 7274 38432 1700936
Haematocrit decreased 112.92 45.54 57 7356 4216 1735152
Prostate cancer 111.51 45.54 58 7355 4568 1734800
Confusional state 109.52 45.54 103 7310 21175 1718193
Prostate cancer metastatic 108.32 45.54 36 7377 895 1738473
Metastases to lymph nodes 106.83 45.54 35 7378 831 1738537
Drug ineffective 106.74 45.54 175 7238 63626 1675742
C-reactive protein increased 106.40 45.54 61 7352 5824 1733544
Hyperglycaemia 105.50 45.54 58 7355 5107 1734261
Bacterial translocation 104.29 45.54 20 7393 36 1739332
Blood pressure decreased 103.98 45.54 66 7347 7580 1731788
Hypoalbuminaemia 99.65 45.54 38 7375 1422 1737946
Nail disorder 99.21 45.54 28 7385 393 1738975
Intestinal ischaemia 96.30 45.54 34 7379 1019 1738349
Non-small cell lung cancer 94.94 45.54 30 7383 632 1738736
Lymphopenia 94.06 45.54 40 7373 1993 1737375
Oesophagitis 94.01 45.54 38 7375 1663 1737705
Back pain 92.37 45.54 84 7329 16529 1722839
Respiratory distress 92.00 45.54 53 7360 5104 1734264
Shock 91.29 45.54 49 7364 4112 1735256
Gastrointestinal haemorrhage 91.02 45.54 78 7335 14189 1725179
Infection 90.10 45.54 73 7340 12287 1727081
Flushing 89.87 45.54 56 7357 6223 1733145
Metastases to liver 89.87 45.54 40 7373 2227 1737141
Hypomagnesaemia 89.57 45.54 39 7374 2059 1737309
Blood sodium decreased 89.25 45.54 40 7373 2264 1737104
Tachycardia 88.73 45.54 73 7340 12555 1726813
Radiation skin injury 88.56 45.54 21 7392 139 1739229
Blood urea increased 88.29 45.54 50 7363 4661 1734707
Radiation pneumonitis 87.04 45.54 25 7388 375 1738993
Bone pain 86.34 45.54 44 7369 3318 1736050
Lung infiltration 85.28 45.54 38 7375 2121 1737247
Urinary tract infection 84.84 45.54 65 7348 10088 1729280
Oxygen saturation decreased 84.73 45.54 52 7361 5623 1733745
Oedema 84.68 45.54 56 7357 6892 1732476
Lung disorder 84.42 45.54 50 7363 5069 1734299
Dizziness 81.27 45.54 111 7302 34250 1705118
Hyperkalaemia 80.95 45.54 59 7354 8488 1730880
Portal venous gas 80.86 45.54 18 7395 86 1739282
Syncope 77.48 45.54 71 7342 14098 1725270
Loss of consciousness 76.44 45.54 72 7341 14803 1724565
Pneumatosis intestinalis 76.28 45.54 24 7389 498 1738870
Epistaxis 75.65 45.54 56 7357 8250 1731118
Intestinal perforation 75.37 45.54 32 7381 1587 1737781
Oral candidiasis 74.95 45.54 30 7383 1279 1738089
Urinary retention 74.39 45.54 47 7366 5348 1734020
Blood lactate dehydrogenase increased 74.28 45.54 41 7372 3634 1735734
Dermatitis 73.76 45.54 32 7381 1674 1737694
Infusion related reaction 72.82 45.54 50 7363 6543 1732825
Sudden death 71.22 45.54 37 7376 2903 1736465
Bacteraemia 70.77 45.54 32 7381 1848 1737520
Cardio-respiratory arrest 67.93 45.54 55 7358 9238 1730130
Aspiration 67.78 45.54 31 7382 1839 1737529
Febrile bone marrow aplasia 67.72 45.54 25 7388 853 1738515
Oesophageal fistula 67.50 45.54 15 7398 71 1739297
Dysgeusia 67.15 45.54 43 7370 5006 1734362
Onychomadesis 66.32 45.54 17 7396 161 1739207
Prostate cancer recurrent 66.08 45.54 16 7397 117 1739251
White blood cell count increased 65.91 45.54 49 7364 7263 1732105
Toxicity to various agents 65.64 45.54 92 7321 29049 1710319
Peritonitis 65.00 45.54 34 7379 2705 1736663
Hiccups 64.82 45.54 28 7385 1449 1737919
Neutropenic colitis 62.91 45.54 18 7395 266 1739102
Hypersensitivity 62.33 45.54 55 7358 10389 1728979
Red blood cell count decreased 60.75 45.54 36 7377 3650 1735718
Atelectasis 60.62 45.54 29 7384 1905 1737463
Metastases to central nervous system 60.39 45.54 27 7386 1518 1737850
Mouth ulceration 60.19 45.54 28 7385 1727 1737641
Gastric perforation 60.17 45.54 19 7394 399 1738969
Leukocytosis 59.52 45.54 35 7378 3498 1735870
Oral pain 59.14 45.54 26 7387 1404 1737964
Aspartate aminotransferase increased 58.97 45.54 54 7359 10702 1728666
Pericardial effusion 58.21 45.54 34 7379 3356 1736012
Neutropenic infection 58.14 45.54 15 7398 146 1739222
Enteritis 58.02 45.54 23 7390 955 1738413
Oesophagobronchial fistula 57.34 45.54 12 7401 40 1739328
Polyneuropathy 57.10 45.54 27 7386 1728 1737640
Enterocolitis 56.30 45.54 22 7391 879 1738489
Lacrimation increased 55.96 45.54 25 7388 1403 1737965
Mediastinitis 55.86 45.54 14 7399 120 1739248
Osteonecrosis 55.82 45.54 35 7378 3927 1735441
Chest X-ray abnormal 55.59 45.54 20 7393 633 1738735
Circulatory collapse 54.90 45.54 33 7380 3434 1735934
Metastasis 54.27 45.54 21 7392 817 1738551
Blood alkaline phosphatase increased 54.08 45.54 38 7375 5157 1734211
Hypertension 53.91 45.54 68 7345 19380 1719988
Gastrointestinal toxicity 52.92 45.54 17 7396 378 1738990
Heart rate increased 52.86 45.54 41 7372 6469 1732899
Capillary leak syndrome 52.77 45.54 16 7397 292 1739076
Hypophosphataemia 51.57 45.54 23 7390 1285 1738083
Lethargy 51.40 45.54 42 7371 7142 1732226
Cardiac arrest 51.13 45.54 60 7353 15870 1723498
Renal impairment 50.97 45.54 53 7360 12261 1727107
Respiratory tract infection 50.88 45.54 28 7385 2465 1736903
Pulmonary fibrosis 50.77 45.54 28 7385 2476 1736892
Atypical haemolytic uraemic syndrome 50.50 45.54 10 7403 23 1739345
Staphylococcal infection 50.32 45.54 35 7378 4672 1734696
Haematemesis 50.23 45.54 34 7379 4343 1735025
Clostridium difficile colitis 50.11 45.54 24 7389 1580 1737788
Small intestinal obstruction 50.08 45.54 25 7388 1802 1737566
Rash 50.02 45.54 95 7318 38598 1700770
Cardiac failure 49.95 45.54 53 7360 12549 1726819
Hypovolaemia 49.52 45.54 22 7391 1218 1738150
Urine output decreased 49.15 45.54 23 7390 1437 1737931
Bacterial infection 49.13 45.54 25 7388 1877 1737491
Acute motor-sensory axonal neuropathy 49.09 45.54 10 7403 28 1739340
Tumour necrosis 49.04 45.54 14 7399 205 1739163
Failure to thrive 48.65 45.54 21 7392 1084 1738284
Metabolic acidosis 48.22 45.54 36 7377 5366 1734002
Tumour lysis syndrome 48.11 45.54 24 7389 1727 1737641
Hydronephrosis 47.80 45.54 22 7391 1323 1738045
Tumour pain 47.77 45.54 13 7400 158 1739210
Nicotinic acid deficiency 47.75 45.54 9 7404 14 1739354
Pancreatitis acute 47.50 45.54 32 7381 4055 1735313
Dyspnoea exertional 46.98 45.54 32 7381 4129 1735239
Abdominal pain lower 46.87 45.54 21 7392 1186 1738182
Abdominal pain upper 46.70 45.54 48 7365 10953 1728415
Chest discomfort 46.53 45.54 40 7373 7291 1732077
Anuria 46.40 45.54 24 7389 1864 1737504
Blood chloride decreased 46.38 45.54 17 7396 568 1738800
Dermatitis acneiform 46.34 45.54 20 7393 1032 1738336
Second primary malignancy 46.21 45.54 20 7393 1039 1738329

Pharmacologic Action:

SourceCodeDescription
ATC L01CD02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Taxanes
MeSH PA D050256 Antimitotic Agents
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:47868 photosensitizing agent
CHEBI has role CHEBI:38068 antimalarial
FDA PE N0000175085 Microtubule Inhibition
FDA EPC N0000175592 Microtubule Inhibitor
MeSH PA D050257 Tubulin Modulators

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908
Carcinoma of breast indication 254838004 DOID:3459
Malignant tumor of head and/or neck indication 255056009
Malignant tumor of stomach indication 363349007 DOID:10534
Malignant tumor of prostate indication 399068003 DOID:10283
Metastatic Breast Carcinoma indication
Ewing's sarcoma off-label use 76909002 DOID:3369
Small cell carcinoma of lung off-label use 254632001 DOID:5409
Malignant tumor of esophagus off-label use 363402007
Malignant tumor of ovary off-label use 363443007 DOID:2394
Invasive Bladder Malignancy off-label use
Refractory Osteosarcoma off-label use
Asthenia contraindication 13791008
Hyperbilirubinemia contraindication 14783006 DOID:2741
Pulmonary edema contraindication 19242006 DOID:11396
Cardiac tamponade contraindication 35304003 DOID:115
Body fluid retention contraindication 43498006
Stomatitis contraindication 61170000 DOID:9637
Diarrhea contraindication 62315008
Acute infectious disease contraindication 63171007
Peripheral motor neuropathy contraindication 95663000 DOID:683
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Peripheral edema contraindication 271809000
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Pleural Effusions contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.9 acidic
pKa2 11.64 acidic
pKa3 12.4 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 8940786 Sept. 30, 2033 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
160MG/8ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 8940786 Sept. 30, 2033 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
20MG/ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 8940786 Sept. 30, 2033 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
80MG/4ML (20MG/ML) DOCETAXEL TEIKOKU PHARMA N205934 Dec. 22, 2015 RX INJECTABLE INJECTION 9763880 Sept. 30, 2033 USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tubulin beta Tumour-associated antigen INHIBITOR ID50 6.70 WOMBAT-PK CHEMBL
Epidermal growth factor receptor Kinase INHIBITOR Kd 9.09 WOMBAT-PK
Cytochrome P450 3A4 Enzyme IC50 5.70 DRUG MATRIX
Substance-K receptor GPCR Ki 6.28 DRUG MATRIX
Multidrug resistance-associated protein 7 Transporter WOMBAT-PK
Multidrug resistance protein 1 Transporter WOMBAT-PK
Growth hormone-releasing hormone receptor GPCR IC50 9.85 CHEMBL

External reference:

IDSource
D000077143 MESH_DESCRIPTOR_UI
4020968 VUID
N0000148441 NUI
C0246415 UMLSCUI
D02165 KEGG_DRUG
15H5577CQD UNII
148408-66-6 SECONDARY_CAS_RN
6621 INN_ID
108806006 SNOMEDCT_US
4020968 VANDF
005187 NDDF
178776 MMSL
72962 RXNORM
d04009 MMSL
180476 MMSL
4626 MMSL
386918005 SNOMEDCT_US
CHEMBL92 ChEMBL_ID
TXL PDB_CHEM_ID
DB01248 DRUGBANK_ID
CHEBI:4672 CHEBI
6809 IUPHAR_LIGAND_ID
CHEMBL3545252 ChEMBL_ID
148124 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TAXOTERE HUMAN PRESCRIPTION DRUG LABEL 1 0075-8003 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS NDA 20 sections
TAXOTERE HUMAN PRESCRIPTION DRUG LABEL 1 0075-8004 INJECTION, SOLUTION, CONCENTRATE 80 mg INTRAVENOUS NDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 0409-0201 INJECTION, SOLUTION 10 mg INTRAVENOUS NDA 21 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 0409-0366 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 21 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 0409-0367 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 21 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 0409-0368 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 21 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 0955-1020 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS NDA authorized generic 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 0955-1021 INJECTION, SOLUTION, CONCENTRATE 80 mg INTRAVENOUS NDA authorized generic 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 0955-1022 INJECTION, SOLUTION, CONCENTRATE 160 mg INTRAVENOUS NDA authorized generic 20 sections
DOCETAXEL HUMAN PRESCRIPTION DRUG LABEL 1 16729-231 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS NDA 20 sections
DOCETAXEL HUMAN PRESCRIPTION DRUG LABEL 1 16729-267 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS NDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 25021-245 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 39822-2120 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS ANDA 19 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 39822-2180 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS ANDA 19 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 39822-2200 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS ANDA 19 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43066-001 INJECTION, SOLUTION 10 mg INTRAVENOUS NDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43066-006 INJECTION, SOLUTION 10 mg INTRAVENOUS NDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43066-010 INJECTION, SOLUTION 10 mg INTRAVENOUS NDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43598-258 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43598-259 INJECTION, SOLUTION 80 mg INTRAVENOUS ANDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43598-389 INJECTION, SOLUTION 160 mg INTRAVENOUS ANDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43598-610 INJECTION, SOLUTION 80 mg INTRAVENOUS ANDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 43598-611 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 45963-734 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS NDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 45963-765 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS NDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 45963-790 INJECTION, SOLUTION, CONCENTRATE 20 mg INTRAVENOUS NDA 20 sections
DOCETAXEL HUMAN PRESCRIPTION DRUG LABEL 1 50742-428 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 20 sections
DOCETAXEL HUMAN PRESCRIPTION DRUG LABEL 1 50742-431 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 20 sections
DOCETAXEL HUMAN PRESCRIPTION DRUG LABEL 1 50742-463 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 20 sections
Docetaxel HUMAN PRESCRIPTION DRUG LABEL 1 57884-3021 INJECTION, SOLUTION, CONCENTRATE 40 mg INTRAVENOUS ANDA 20 sections